The AR is important for therapeutic target in prostate cancer , thus many different inhibitors have been developed, primarily targeting the ligand binding domain of the protein, while inhibitors that target the N-terminal domain of the protein are still under development.  AR ligands can either be classified based on their structure ( steroidal or nonsteroidal ) or based on their ability to activate or inhibit transcription ( agonists or antagonists ).  Sulforaphane , a phytochemical derived from broccoli or the HSP90 inhibitor ganetespib or the NRF2 activator bardoxolone methyl has been shown to degrade both AR and AR-V7 and thus enhance the efficacy of antagonists like enzalutamide.  
SPL documents contain both the content of labeling (all text, tables and figures) for a product along with additional machine readable information (including drug listing data elements and clinical data elements). Drug listing data elements include coded information about the product (including product and generic names, ingredients, ingredient strengths, dosage forms, routes of administration, appearance, DEA schedule) and the packaging (package quantity and type). Clinical data elements include coded information about the clinical use of the product (including indications and use, contraindications, drug interactions, warning and precautions and use in special populations).
Estradiol's efficacy seems to vary widely with the person and the particular vehicle: I was on transdermal patches for two years ( , 2 patches changed twice weekly – considered a "high" dose of 17-beta estradiol), and my levels mostly stayed around 100 pg/mL, and I needed 100mg spironolactone daily to keep my testosterone down. When I switched to injections of Estradiol Valerate, as I was "titrating up" my testosterone was unmeasurably low at the same E2 level my patches were delivering. (I had decided to drop spiro at the same time due to it's side effects: for me it seemed to be fogging my brain and inducing suicidal ideation.) Increasing the dosage had the effect of adding a cup-size to my breasts after about two months of injections, after two years of HRT, at age 53 and with b-cup breasts already. This story is not unusual in the community, and it led me to try this form of HRT.